A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group STudy to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA - Intervention Trial)
